Search Within

Samuel Aaron Funt

Formats
  1. Meeting Abstract (70)
  2. Journal Article (59)
  3. Review (3)
  4. Correspondence (2)
  5. Editorial (1)
Groups
  1. Department of Medicine (135)
  2. Genitourinary Oncology Service (135)
  3. Solid Tumor Oncology Division (135)
  4. Weinberg Fellows (135)
  5. Department of Pathology and Laboratory Medicine (74)
  6. Surgery (60)

More Groups

People
  1. Dean Bajorin (87)
  2. Jonathan Rosenberg (71)
  3. Gopakumar Iyer (62)
  4. Hikmat Al-Ahmadie (54)
  5. Darren Feldman (47)
  6. Min Yuen Teo (46)

More People

Years
  1. 2025 (2)
  2. 2024 (19)
  3. 2023 (13)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (70)
  2. Annals of Oncology (4)
  3. Clinical Cancer Research (4)
  4. European Urology (3)
  5. JCO Precision Oncology (3)
  6. Nature Communications (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (73)
  2. Elsevier Science, Inc. (8)
  3. Nature Publishing Group (7)
  4. American Association for Cancer Research (6)
  5. Elsevier Inc. (6)
  6. Oxford University Press (5)

More Publishers

Results (135)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT)
    Meeting Abstract

    Dean, L. W.; Wong, N. C.; Dason, S.; Isharwal, S.; Donoghue, M.; Jia, L.; Tap, W. D.; Joseph, G.; Funt, S. A.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration
    Meeting Abstract

    Funt, S. A.; Solovyov, A.; Faltas, B. M.; Iyer, G.; Boyd, M. E.; Cipolla, C. K.; Regazzi, A. M.; Teo, M. Y.; Lee, C. H.; Al-Ahmadie, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma
    Meeting Abstract

    Almassi, N.; Pietzak, E. J.; Funt, S. A.; Schultz, N.; Dalbagni, G.; Bochner, B. H.; Al-Ahmadie, H.; Bajorin, D. F.; Rosenberg, J. E.; Iyer, G.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Impact of teratoma on the cumulative incidence of disease-related death in patients with advanced germ cell tumors
    Journal Article

    Funt, S. A.; Patil, S.; Feldman, D. R.; Motzer, R. J.; Bajorin, D. F.; Sheinfeld, J.; Tickoo, S. K.; Reuter, V. E.; Bosl, G. J.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: Concordance among 3 commonly used and commercially available antibodies
    Journal Article

    Reis, H.; Serrette, R.; Posada, J.; Lu, V.; Chen, Y. B.; Gopalan, A.; Fine, S. W.; Tickoo, S. K.; Sirintrapun, S. J.; Iyer, G.; more...
    American Journal of Surgical Pathology (2019)

    Fulltext@MSK | Save
  • The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer
    Review

    van Dijk, N.; Funt, S. A.; Blank, C. U.; Powles, T.; Rosenberg, J. E.; van der Heijden, M. S.
    European Urology (2019)

    Fulltext@MSK | Save
  • Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy
    Editorial

    Pietzak, E. J.; Zabor, E. C.; Bagrodia, A.; Armenia, J.; Hu, W.; Zehir, A.; Funt, S.; Audenet, F.; Barron, D.; Maamouri, N.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)
    Meeting Abstract

    Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save